Novel Targeted Therapy for Neuroblastoma: Silencing the MXD3 Gene Using siRNA

BACKGROUND: Neuroblastoma is the second most common extracranial cancer in children. Current therapies for neuroblastoma, which use a combination of chemotherapy drugs, have limitations for high-risk subtypes and can cause significant long-term adverse effects in young patients. Therefore, a new the...

Descripción completa

Detalles Bibliográficos
Autores principales: Duong, Connie, Yoshida, Sakiko, Chen, Cathy, Barisone, Gustavo, Diaz, Elva, Li, Yueju, Beckett, Laurel, Chung, Jong, Antony, Reuben, Nolta, Jan, Nitin, Nitin, Satake, Noriko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766270/
https://www.ncbi.nlm.nih.gov/pubmed/28419087
http://dx.doi.org/10.1038/pr.2017.74

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5766270/
https://www.ncbi.nlm.nih.gov/pubmed/28419087
http://dx.doi.org/10.1038/pr.2017.74

Ejemplares similares